1 TITLE

4

5

7

8

16 17

- 2 Solicited Cough Sound Analysis for Tuberculosis Triage Testing: The CODA TB
- 3 DREAM Challenge Dataset

RUNNING TITLE

6 Cough sounds for tuberculosis triage

AUTHORS

- 9 Sophie Huddart^{1*}, Vijay Yadav^{2*}, Solveig K. Sieberts², Larson Omberg^{2,3}, Mihaja
- 10 Raberahona^{4,5}, Rivo Rakotoarivelo^{6,7}, Issa N. Lyimo⁸, Omar Lweno⁸, Devasahayam J
- 11 Christopher⁹, Nguyen Viet Nhung¹⁰, Grant Theron¹¹, William Worodria¹², Charles Y.
- 12 Yu¹³, Christine M Bachman¹⁴, Stephen Burkot¹⁴, Puneet Dewan¹⁴, Sourabh Kulhare¹⁴,
- 13 Peter M Small¹⁴, Adithya Cattamanchi¹⁵, Devan Jaganath^{15#}, Simon Grandjean
- 14 Lapierre^{16,17#}
- 15 *, *Equal contributions

AFFILIATIONS

- ¹University of California San Francisco, School of Medicine, 533 Parnassus Ave, San
- 19 Francisco, CA 94143 USA
- 20 ²Sage Bionetworks, Seattle, WA 98103 USA
- 21 ³Curently at Koneksa Health, One World Trade Center 285 Fulton St. 77th Floor New
- 22 York, NY, 10007
- 23 ⁴CHU Joseph Rasera Befelatanana, Antananarivo, 101, Analamanga, Madagascar
- ⁵Centre d'Infectiologie Charles Mérieux, Antananarivo, 101, Analamanga, Madagascar
- 25 ⁶CHU Tambohobe Fianarantsoa, 301, Haute-Matsiatra, Madagascar
- ⁷Université de Fianarantsoa, Fianarantsoa, 301, Haute-Matsiatra, Madagascar
- 27 ⁸Ifakara Health Institute, Environmental and Ecological Sciences & Interventions and
- 28 Clinical Trials Departments, Kiko Avenue, Plot 463, Mikocheni, Dar es Salaam,
- 29 Tanzania
- 30 ⁹Christian Medical College, Ida Scudder Road, Vellore 632004, Tamil Nadu, India
- 31 ¹⁰National Tuberculosis Programme, 463 Hoang Hoa Tham, Ba Dinh District, Hanoi,
- 32 Vietnam

- 33 ¹¹Stellenbosch University, Division of Molecular Biology and Human Genetics,
- 34 Matieland, 7602 South Africa
- 35 ¹²Walimu, Plot 5-7, Coral Crescent, Kololo, Kampala, Uganda
- 36 ¹³De La Salle Medical and Health Sciences Institute, Governor D. Mangubat Avenue,
- 37 Dasmarinas Cavite, Philippines 4114
- 38 ¹⁴Global Health Labs, 14360 SE Eastgate Way, Bellevue, WA 98007 USA
- 39 ¹⁵University of California Irvine, School of Medicine, 333 City Blvd. W Suite 400, Orange
- 40 CA 92868 USA
- 41 ¹⁶Centre de Recherche du Centre Hospitalier de l'Université de Montréal,
- 42 Immunopathology Axis, 900 St-Denis, Montréal, Québec, H2X 0A9 Canada
- 43 ¹⁷Université de Montréal, Department of Microbiology, Infectious Diseases and
- 44 Immunology, 2900 Edouard-Montpetit, Montréal, Québec, H3T 1J4 Canada

CORRESPONDING AUTHOR

- 47 Simon Grandjean Lapierre
- 48 Simon.grandjean.lapierre@umontreal.ca
- 50 WORD COUNT
- 51 2286

45

46

ABSTRACT

Cough is a common and commonly ignored symptom of lung disease. Cough is often perceived as difficult to quantify, frequently self-limiting, and non-specific. However, cough has a central role in the clinical detection of many lung diseases including tuberculosis (TB), which remains the leading infectious disease killer worldwide. TB screening currently relies on self-reported cough which fails to meet the World Health Organization (WHO) accuracy targets for a TB triage test. Artificial intelligence (AI) models based on cough sound have been developed for several respiratory conditions, with limited work being done in TB. To support the development of an accurate, point-of-care cough-based triage tool for TB, we have compiled a large multi-country database of cough sounds from individuals being evaluated for TB. The dataset includes more than 700,000 cough sounds from 2,143 individuals with detailed demographic, clinical and microbiologic diagnostic information. We aim to empower researchers in the development of cough sound analysis models to improve TB diagnosis, where innovative approaches are critically needed to end this long-standing pandemic.

BACKGROUND AND SUMMARY

68

69

70

71

72

73

74

75

76

77

78 79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

Tuberculosis remains the leading infectious disease killer globally, partly due to public health systems' inability to accurately diagnose millions of infected individuals every year. Insufficient access to high-quality TB screening and diagnosis is recognized as one of the most important gaps in the cascade of care. Here we describe a cough sound database including detailed demographic, clinical and microbiologic information for the development of Al-based sound classification TB triage models. As the WHO's End TB Strategy calls for intensified research and innovation including the discovery of new tools for community-based screening, digital cough monitoring and *Acoustic Epidemiology* could represent new tools that can help bend the TB pandemic curve and accelerate the achievement of global TB elimination goals. 3-5

The "missing millions" of undiagnosed patients living with active TB disease represent an heterogeneous group including those who did not access triage or diagnosis testing or weren't appropriately referred for effective treatment. Improving the accuracy, portability, point-of-care amenability and connectivity of diagnostic tools and algorithms would have significant value. Most health systems build their TB programs on a combination of complementary screening followed by diagnostic tests. The WHO's target product profile (TPP) for a community-based TB triage test suggests that it should be at least 90% sensitive and 70% specific. According to the 2021 WHO TB screening guidelines, symptom-based screening with guestionnaires, including cough, is 42% sensitive. Besides having poor accuracy these guidelines have operational challenges that impede its sustained and uniform implementation within resource-challenged TB programs. Other tools such as digital chest X-rays combined with computer-aided detection (CAD) algorithms have also been evaluated in the context of TB triage. This approach was shown to be highly sensitive but had variable specificity and remains difficult to deploy due to limited availability of chest X-ray platforms at primary-level health facilities.8 Whether in the context of community-based outreach screening or healthcare facility-based evaluation prior to confirmatory testing, cough classification models could complement or replace other triage strategies including symptom-based screening.

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

We historically have been unable to objectively monitor cough sounds and consequently reduced this data-rich symptom into subjective and dichotomous information (e.g., cough versus no cough, chronic versus acute, better versus worse). Advances in acoustics and machine learning (ML) have enabled the identification and recording of human coughs in real-world acoustic environments (cough detection) as well as differentiation of coughs from patients with distinct clinical conditions or at different stages of disease (cough classification). As part of the emerging field of Acoustic Epidemiology, this has the potential to develop novel screening or diagnostic assays with simple digital recording devices, such as a smartphone, tablet or watch.⁵ Proof-ofconcept studies previously showed that cough associated with TB contains a specific acoustic signature which can be recognized by ML models. A study by Pahar et al. suggests that a cough-based TB screening model can discriminate TB cough sounds from those associated with other lung conditions with 93% sensitivity and 95% specificity, exceeding the WHO TPPs. In a study combining cough sound analysis and patients' clinical characteristics, Yellapu et al. report that ML can be used to detect TB with 90% sensitivity and 85% specificity. 10 Those pilot studies report on ML models which were designed on small datasets and were not validated in external populations. Given the potential impact on performance of local disease epidemiology and population ethnicity among other confounders, large and diverse cough datasets are needed to replicate those studies.

We collected and are here releasing a dataset including 733,756 cough sounds from 2,143 patients across 7 countries with accurately annotated demographic, clinical and microbiologic diagnostic information. These data were initially used to enable and evaluate the CODA TB DREAM Challenge which invited participants to develop algorithms for prediction of TB diagnosis. The training data are now available for general use, and researchers are invited to leverage acoustic and clinical data to further develop and evaluate sound classification models for TB screening against a held-out test partition. We aim to enable the development of models which could achieve the WHO TPP performance targets for the current 'community-based TB triage test' or the forthcoming TPP for a TB screening test. Find the data set has limitations which include some selection bias since it was collected from a symptomatic presumptive TB

population. The developed models which will be developed may hence not perform as well if used for asymptomatic screening at population level. Accordingly, more data should be collected from community screening activities.

METHODS

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

Participants

A total of 2,143 participants were recruited from two parent studies described below. To be eligible, participants had to be 18 years or older and have a new or worsening cough for at least two weeks. took place at outpatient clinics in India, Madagascar, the Philippines, South Africa, Tanzania, Uganda, and Vietnam. All participants provided informed consent. A summary of participant demographics and country distribution are available in Table 1.

Rapid Research in Diagnostic Development TB Network (R2D2 TB Network) study: The R2D2 TB Network study evaluates novel TB diagnostics in various stages of development among people with presumptive TB in five low- and middle-income countries: Uganda, South Africa, Vietnam, the Philippines and India. 13 Ethical approval for this study was obtained from institutional review boards (IRB) in the US and in each study site. In the US, approval was obtained from the University of California San Francisco IRB (# 20-32670). In Vietnam, approval was obtained from the Ministry of Health Ethical Committee for National Biological Medical Research (94/CN-HĐĐĐ), the National Lung Hospital Ethical Committee for Biological Medical Research (566/2020/NCKH) and the Hanoi Department of Health, Hanoi Lung Hospital Science and Technology Initiative Committee (22/BVPHN). In India, approval was obtained from Christian Medical College IRB (13256). In South Africa, approval was obtained from Stellenbosch University Health Research Ethics Committee (17047). In Uganda, approval was obtained from Makerere University, College of Health Sciences, School of Medicine, Research Ethics Committee (2020-182). In the Philippines, approval was obtained from De La Salle Health Sciences Institute Independent Ethics Committee (2020-33-02-A).

The Digital Cough Monitoring for screening, diagnosis and clinical follow-up of tuberculosis and other respiratory diseases project: This project was designed to embed digital cough monitoring within existing health facility-based TB diagnostic cohorts in Madagascar and Tanzania. Ethical approval for this study was obtained from institutional review boards (IRB) in Canada and in each study site. In Canada, approval was obtained from the Centre de Recherche du Centre Hospitalier de l'Université de Montréal IRB (# 2021-9270, 20.226). In Madagascar, approval was obtained from the d'Éthique Biomédicale à la Recherche (IORG0000851 MSANP/SG/AMM/CERBM).). In Tanzania, approval was obtained from the Ifakarah Health Institute IRB (31-2021) and the National Institute for Medical Research (NIMR/HQ/R.8a/Vol IX/3805).

Data Collection

Demographic and clinical data. At enrollment into the parent studies, participants underwent a baseline questionnaire, clinical examination, and sputum collection for TB testing. Study staff also recorded participants' age, gender, height, weight, smoking status and duration of cough. HIV diagnosis was made either based on participant self-report of a positive HIV diagnosis or a positive test result. A summary of the available variables is shown in Table 2.

TB Reference Standard Testing. Both Xpert MTB/RIF Ultra PCR and mycobacterial culture (Lowenstein-Jensen solid medium or MGIT liquid medium) were performed on sputum collected from all participants. Any participant whose first sputum Xpert MTB/RIF Ultra result was indeterminate or trace-positive, received a second sputum Xpert MTB/RIF Ultra test. Results from those assays were combined to determine TB status according to two reference standards: a microbiologic reference standard and a sputum Xpert reference standard. The sputum Xpert reference standard is restricted to Xpert MTB/RIF Ultra results on sputum samples. The microbiologic reference standard includes culture results, allowing for more individuals to be classified as TB positive. The microbiologic reference standard is considered the primary reference standard. Full details of the reference standards are described in Table 3.

Cough Recording. Cough sounds were collected using smartphones loaded with the Hyfe research app. 14 Specific phone models used in the different participating sites are presented in Supplementary Materials 1. Hyfe research app is designed to listen for explosive sounds and record ~0.5 seconds sound fragments corresponding to putative cough sounds. Hyfe research app uses a server-based convolutional neural network (CNN) model to classify explosive sounds as coughs and recordings of these cough sounds are saved on a protected health information (PHI)-regulated server for analysis. This model has been shown to be 96% sensitive and 96% specific for cough detection using human-labeled sounds as a reference standard. Smartphones were positioned on tripods in rooms within the clinic. Participants were asked to cough five times (solicited cough) while standing 60-90 cm from the tripod; participants who managed to produce at least three coughs were retained in the dataset. Some participants produced more than five coughs due to a triggered coughing fit and those additional coughs were also collected and included in the dataset. Solicited and triggered coughs could not be labeled distinctively and are treated the same in the dataset. After enrollment and onboarding, a subset of participants (n = 565) were also asked to carry a study phone for two weeks and collect longitudinal coughs sounds in an outpatient setting. Those sounds are labeled as longitudinal and made available within the dataset. A tally of solicited and longitudinal cough sounds per data partition are available in Table 4.

Data Partitioning

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

The dataset was split into a training (n=1,105) and validation set (n=1,038). The dataset was randomly partitioned evenly between the training and testing set at the level of the participant (i.e., all of a participant's cough sounds are in either the training or validation set).

Data Pre-Processing

Cough sounds: The sound recordings available in this dataset have not undergone preprocessing beyond their identification as a cough sound by the Hyfe research app CNN model. Clinical Data: Data from all participating sites were collected with standardized questionnaires and definitions. Data formatting was harmonized in the open access database.

Dataset Description

Sage Bionetworks independently verified the variable balance between the training and validation sets as demonstrated in Table 1. A breakdown of key demographics and microbiologic reference standard results by country are shown in Table 5.

DATA RECORDS

De-identified participant demographic and clinical data, including TB reference standard results, cough sound WAV files, and a datafile linking participant IDs to sound file IDs were exported to a dedicated project in Synapse. Synapse is a general-purpose data and analysis sharing service where members can work collaboratively, analyze data, share insights, and have attributions and provenance of those insights to share with others. Synapse is developed and operated by Sage Bionetworks¹⁶. A total of 1,105 participants' data are made available for access and download as a training dataset. The validation set is withheld, but models can be evaluated against the validation set via the instructions provided in the Synapse project.

All training set files are stored and are accessible via the Synapse platform with associated metadata and documentation and can be accessed at the following URL: www.synapse.org/TBcough - https://doi.org/10.7303/syn31472953.

TECHNICAL VALIDATION

All cough collection periods were observed by study staff and cough sounds were spotchecked for accurate recording. Patient metadata was reviewed by study staff for accuracy. The data described in this article were collected using the Hyfe Research app which uses a proprietary algorithm to identify cough sounds. We used a prediction score of 0.8 from this algorithm to filter potential non-cough sounds. To validate the precision of the Hyfe algorithm, a standalone computer vision and deep learning model was trained using Log Mel spectrogram images from ESC-50 and Coswara datasets. The "VGG16" CNN based pre-trained model was trained for accurate classification of cough sounds and achieved a model accuracy of approximately 96% on Hyfe cough recordings. Most of the recordings that were classified incorrectly had a Hyfe prediction score less than 0.8.

USAGE NOTES

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

285

286

289

290

Users can register to evaluate predictive models of TB diagnosis against the held-out test partition via the instructions on the Synapse project. The scoring mechanism can evaluate two different types of models: (1) those that use only cough sounds, or (2) those which also incorporate clinical metadata variables which have been provided in the training dataset (sex, age, height, weight, reported duration of cough, prior TB diagnosis and type, hemoptysis, heart rate, temperature, weight loss, smoking in the last week, fever and night sweats). Models are submitted to the scoring queues as Docker images. Full instructions and example code is available on Synapse project website (www.synapse.org/TBcough).

Downloading the Data

Given the number of files represented in the data, users should consider downloading the data via one of the programmatic Synapse clients (available in R or Python). For convenience, Python code for downloading the data is provided in the Synapse project wiki. The training dataset size is (0.43 GB) for the solicited coughs and (31.6 GB) for the longitudinal coughs.

Data Use Agreement

- 281 To access the data, individuals must become Certified and Validated users of Synapse
- and maintain an active account on Synapse: http://www.synapse.org. They must also
- submit an Intended Data Use Statement and agree to the Terms of Use of the dataset.
- Terms of Use are summarized in Supplementary Materials 2.

CODE AVAILABILITY

No additional data processing was conducted other than what has been described above.

DATA AVAILABILITY

- 291 All training set files are stored and are accessible via the Synapse platform with
- 292 associated metadata and documentation and can be accessed at the following URL:
- 293 <u>www.synapse.org/TBcough</u>.

294 295 Specific acoustic and clinical metadata as well as dataset information can be found 296 under the following doi references. 297 Clinical data: https://doi.org/10.7303/syn53710097 298 Cough metadata: https://doi.org/10.7303/syn53710098 299 Solicited Coughs: https://doi.org/10.7303/syn40358494 300 Longitudinal Coughs: https://doi.org/10.7303/syn40358476 301 Data Dictionary: https://doi.org/10.7303/syn41743692 302 Data sharing and model benchmarking website: https://doi.org/10.7303/syn31472953

REFERENCES

- 304 1 WHO. Global TB report 2023. (2023).
- Faust, L. et al. Improving measurement of tuberculosis care cascades to enhance people-centred care. Lancet Infect Dis 23, e547-e557, doi:10.1016/S1473-3099(23)00375-4 (2023).
- Houben, R. *et al.* Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. *Lancet Glob Health* **4**, e806-e815, doi:10.1016/S2214-109X(16)30199-1 (2016).
- 312 4 WHO. The end TB strategy. (2015).
- 313 5 Zimmer, A. J. *et al.* Making cough count in tuberculosis care. *Commun Med* 314 (*Lond*) **2**, 83, doi:10.1038/s43856-022-00149-w (2022).
- WHO. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. (2014).
- 317 7 WHO. WHO operational handbook on tuberculosis. Module 2: screening systematic screening for tuberculosis disease. (2021).
- 319 Tavaziva, G. et al. Chest X-ray Analysis With Deep Learning-Based Software as 8 320 a Triage Test for Pulmonary Tuberculosis: An Individual Patient Data Meta-321 Clin Infect **74**. Analysis of Diagnostic Accuracy. Dis 1390-1400, 322 doi:10.1093/cid/ciab639 (2022).
- Pahar, M. *et al.* Automatic cough classification for tuberculosis screening in a real-world environment. *Physiol Meas* **42**, doi:10.1088/1361-6579/ac2fb8 (2021).
- Yellapu, G. D. *et al.* Development and clinical validation of Swaasa Al platform for screening and prioritization of pulmonary TB. *Sci Rep* **13**, 4740, doi:10.1038/s41598-023-31772-9 (2023).
- 328 11 Bionetworks, S. CODA TB DREAM Challenge, < www.synapse.org/TBcough> 329 (2024).
- 330 12 WHO. Public consultation for Target Product Profiles for TB screening tests,
 331 https://www.who.int/news-room/articles-detail/public-consultation-for-target-product-profiles-for-tb-screening-tests> (2024).
- 333 13 R2D2. Rapid Research in Diagnostics Development for TB Network, 334 https://www.r2d2tbnetwork.org/> (2024).
- 335 14 HyfeAI. *Hyfe AI*, < https://www.hyfe.ai/> (2024).
- Gabaldon-Figueira, J. C. *et al.* Digital acoustic surveillance for early detection of respiratory disease outbreaks in Spain: a protocol for an observational study. *BMJ Open* **11**, e051278, doi:10.1136/bmjopen-2021-051278 (2021).
- Omberg, L. *et al.* Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. *Nat Genet* **45**, 1121-1126, doi:10.1038/ng.2761 (2013).
- 342 17 Piczak, K. Dataset for Environmental Sound Classification. *Proceedings of the* 343 23rd ACM international conference on Multimedia, doi:doi.org/10.1145/2733373.2806390 (2015).
- 345 18 Bhattacharya, D. *et al.* Coswara: A respiratory sounds and symptoms dataset for remote screening of SARS-CoV-2 infection. *Sci Data* **10**, 397, doi:10.1038/s41597-023-02266-0 (2023).

348 19 Simonyan K., Z. A. Very deep convolutional networks for large-scale image recognition. *conference paper @CLR2015*, doi:https://doi.org/10.48550/arXiv.1409.1556 (2015).

352 **TABLES**

353

Table 1 – Participant demographics across training and test sets

	Training set (N=1105)	Testing set (N=1038)	Complete set (N=2143)
Sex			
Female	517 (46.8%)	460 (44.3%)	977 (45.6%)
Male	588 (53.2%)	578 (55.7%)	1166 (54.4%)
Age			
Median [Q1, Q3]	40.0 [28, 53]	40.0 [29, 53]	40.0 [28, 53]
Height (cm)			
Median [Q1, Q3]	162 [155, 168]	162 [156, 168]	162 [156, 168]
Weight (Kg)			
Median [Q1, Q3]	55.0 [49, 65]	56.0 [49, 65]	55.8 [49, 65]
HIV status			
Negative	878 (79.5%)	809 (77.9%)	1687 (78.7%)
Positive	162 (14.7%)	155 (14.9%)	317 (14.8%)
Unknown	65 (5.9%)	74 (7.1%)	139 (6.5%)
Duration of cough (days)			
Median [Q1, Q3]	30.0 [16, 60]	30.0 [16, 50]	30.0 [16, 60]
Prior TB			
No	903 (81.7%)	835 (80.4%)	1738 (81.1%)
Not sure	3 (0.3%)	2 (0.2%)	5 (0.2%)
Yes	199 (18.0%)	201 (19.4%)	400 (18.7%)
Country			
India	119 (10.8%)	122 (11.8%)	241 (11.2%)
Madagascar	159 (14.4%)	75 (7.2%)	234 (10.9%)
The Philippines	198 (17.9%)	190 (18.3%)	388 (18.1%)
South Africa	137 (12.4%)	138 (13.3%)	275 (12.8%)
Tanzania	87 (7.9%)	110 (10.6%)	197 (9.2%)
Uganda	242 (21.9%)	245 (23.6%)	487 (22.7%)

	Training set (N=1105)	Testing set (N=1038)	Complete set (N=2143)
Vietnam	163 (14.8%)	158 (15.2%)	321 (15.0%)
Microbiologic reference standard			
TB Negative	807 (73.0%)	782 (75.3%)	1589 (74.1%)
TB Positive	297 (26.9%)	256 (24.7%)	553 (25.8%)
Sputum Xpert reference standard			
Indeterminate	4 (0.4%)	2 (0.2%)	6 (0.3%)
TB Negative	839 (75.9%)	808 (77.8%)	1647 (76.9%)
TB Positive	262 (23.7%)	226 (21.8%)	488 (22.8%)

Table 2 - Available demographic, clinical and microbiologic variables

Variable	Values	Format/Definition			
Country	Philippines Vietnam South Africa Uganda India Madagascar Tanzania	Country where the participant was enrolled			
Sex	Male Female	Sex at birth reported by participant			
Age	Numeric	Age calculated as date of collection - date of birth if known. If date of birth is unknown, reported age at time of collection.			
Height	Numeric	Height in centimeters			
Weight	Numeric	Weight in Kg			
HIV status	Positive Negative	HIV status. All participants who do not report being HIV-positive receive HIV testing (using capillary or venous blood) Positive = Positive reported by patient or positive on a HIV test Negative = Negative on a HIV test			
Reported duration of cough	Numeric	Self-reported duration of current cough (days). At baseline, we ask: How many days have you had this new cough or cough that has been worse?			
Prior TB	Yes No	Self-reported. At baseline, we ask: Have you ever had or been told you had tuberculosis (TB)?			
Prior TB type: Pulmonary	Checked Unchecked	Asked at baseline: "With what kind of TB were you diagnosed?" (may select more than one) Participant selected pulmonary TB.			
Prior TB type: Extrapulmonary	Checked Unchecked	Asked at baseline: "With what kind of TB were you diagnosed?" (may select more than one) Participant selected pulmonary TB.			
Prior TB type: Unknown	Checked Unchecked	Asked at baseline: "With what kind of TB were you diagnosed?" (may select more than one) Participant selected Unknown.			
Thor ib type. Officiowif	Yes	In the past 30 days, have you ever coughed			
Hemoptysis	No	up blood?			
Heart rate	Numeric	Participant's heartrate (beats per minute) measured at baseline			
Temperature	Numeric	Participant's temperature (Celsius) measured at baseline.			
Weight loss	Yes No	Subjective, Self-reported. At baseline, we ask: In the past 30 days, have you experienced any weight loss?			
vvoigiit 1000		experienced any weight loss:			

Smoked in last week	Yes No	Asked at baseline "Have you used combustible tobacco and/or vaping products in the last 7 days?"
	Yes	Self-reported fever at baseline: "In the past
Fever	No	30 days, have you ever felt or experienced fever?"
	Yes	Self-reported night sweats at baseline: "In
	No	the past 30 days, have you ever
Night sweats		experienced night sweats?"
Microbiologic reference standard*	TB Positive	TB diagnosis based on sputum and culture
	TB Negative	results
	Indeterminate	
	Positive	TB diagnosis based on sputum results
Sputum Xpert reference	Negative	alone
standard*	Indeterminate	
	Trace	Highest semiquantitative result from sputum
	Very Low	Xpert Ultra test conducted at baseline visit.
	Low	A semiquantitative result will only be
	Medium	available if the test was positive.
Xpert combined semi-quant	High	·

Table 3 – Reference standard definitions

Result	Microbiologic Reference Standard	Sputum Xpert Reference Standard		
TB positive	 One or more of the following: a positive sputum Xpert result a positive urine Xpert result a positive liquid culture result a positive solid culture result a positive Xpert Ultra results on contaminated liquid culture two trace positive Xpert Ultra results on any sample type. 	One of the following:		
TB negative	No positive results on any Xpert or Xpert Ultra testing and one of the following conditions: • two negative liquid cultures • two negative solid cultures • one negative liquid and one negative solid cultures	A negative sputum Xpert result		
Indeterminate	No positive results on any Xpert or Xpert Ultra testing and only one trace result on Xpert Ultra testing of any sample type	An indeterminate or trace- positive sputum Xpert result followed by a non-positive result on repeat sputum Xpert Ultra testing		

Table 4 – Number of cough recordings per data partition

	Training set	Testing set
Solicited coughs (Participants)	9,772 (1,082)	9,062 (1,038)
Longitudinal coughs	714,922 (565)	0 (0)
(participants)		

Longitudinal coughs are not used for evaluation on the testing set, so are not quantified here.

Table 5 – Key variables summarized by country

	India n = 241	Madagascar n = 234	Philippines n = 388	South Africa n = 275	Tanzania n = 197	Uganda n = 487	Vietnam n = 321
Sex							
Female	100 (41%)	115 (49%)	208 (54%)	144 (52%)	86 (44%)	203 (42%)	121 (38%)
Male	141 (59%)	119 (51%)	180 (46%)	131 (48%)	111 (56%)	284 (58%)	200 (62%)
Age							
Median [Q1, Q3]	47 [34, 58]	32 [24, 51]	39 [26, 53]	40 [32, 49]	40 [31, 50]	32 [26, 42]	54 [41, 64]
Duration of cough (days)							
Median [Q1, Q3]	45 [30, 90]	30 [17, 60]	21 [15, 30]	21 [14, 28]	30 [14, 30]	30 [16, 60]	30 [30, 90]
Prior TB							
No	204 (85%)	207 (88%)	325 (84%)	170 (62%)	147 (75%)	427 (88%)	258 (80%)
Not sure	0 (0%)	0 (0%)	4 (1.0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.3%)
Yes	37 (15%)	27 (12%)	59 (15%)	105 (38%)	50 (25%)	60 (12%)	62 (19%)
Microbiologic reference standard							
TB Negative	216 (90%)	131 (56%)	348 (90%)	223 (81%)	161 (82%)	313 (64%)	199 (62%)
TB Positive	25 (10%)	103 (44%)	40 (10%)	52 (19%)	36 (18%)	174 (36%)	122 (38%)

359

362

SUPPLEMENTARY MATERIALS 365 Supplementary materials 1 - Phone models used in the different participating 366 367 sites 368 India 369 Redmi 9 Prime 370 Realme Narzo20 371 Madagascar 372 Motorola G9 play 373 **Philippines** Myphone myWX2 Pro 374 - Xiaomi 9C 375 376 South Africa 377 Nokia 3.1 Nokia 5.4 378 379 Xiaomi Redmi 9A 380 Tanzania 381 Nokia 3.4 Ta-1288 382 Uganda 383 Motorola G16 384 Samsung M11 385 Nokia model 5.3 386 Vietnam 387 - OPPOA54

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

Supplementary materials 2 – Data Use Agreement Researchers wishing to access the data must: You must reaffirm your commitment to the Synapse Pledge and must abide by the guiding principles for responsible research use and data handling within the Synapse Commons Platform as described in the Synapse Governance documents. You will not attempt to establish the identity of, or attempt to contact any of the subjects included in the data. You confirm that if you inadvertently receive identifiable information or otherwise identify a subject, you will promptly notify the ACT by emailing act@sagebase.org. You agree to establish appropriate administrative, technical, and physical safeguards to prevent unauthorized use of or access to the Data. You will report any data misuse or breach of data security to ACT by emailing act@sagebase.org. You will use the data only as identified in your intended data use statement (IDU), submitted through Synapse. The IDU should be written in English and must describe the objectives of the proposed research and study design and analysis plan (500 word maximum). Data accessors must acknowledge the following in all publications or presentations as follows: "The datasets used for the analyses described were contributed by Dr. Adithya Cattamanchi at UCSF and Dr. Simon Grandjean Lapierre at University of Montreal and were generated in collaboration with researchers at Stellenbosch University (PI Grant Theron), Walimu (PIs William Worodria and Alfred Andama); De La Salle Medical and Health Sciences Institute (PI Charles Yu), Vietnam National Tuberculosis Program (Pl Nguyen Viet Nhung), Christian Medical College (PI DJ Christopher), Centre Infectiologie Charles Mérieux Madagascar (PIs Mihaja Raberahona & Rivonirina Rakotoarivelo), and Ifakara Health Institute (PIs Issa Lyimo & Omar Lweno) with funding from the U.S. National Institutes of

420 Health (U01 Al152087), The Patrick J. McGovern Foundation and Global Health 421 Labs." 422 423 **ACKNOWLEDGMENT** 424 We thank all patients and families who participated in this study. We thank healthcare 425 providers, research personnel, laboratory technicians involved in patient recruitment 426 and data collection. 427 428 Funders / operations 429 Data from the CODA TB DREAM Challenge was generated with support from Global 430 Health Labs, the Patrick J. McGovern Foundation, and the National Institute of Allergy 431 and Infectious Diseases of the US National Institutes of Health under award number 432 U01AI152087. The CODA TB DREAM Challenge and post-challenge evaluation was 433 funded in part by the Bill & Melinda Gates Foundation. 434 435 Direct salary support 436 SGL is supported by a Junior 1 Salary Award from the Fonds de Recheche Santé 437 Québec. DJ is supported by funding by the National Institutes of Health 438 439 **AUTHOR CONTRIBUTION** 440 Conception (SKS, LO, CB, PD, PMS, AC, SGL), data acquisition (MR, RR, IL, OL, DJC, 441 NVN, GT, WW, CY), data analysis (SH, VY, SKS, SK, DJ), data interpretation (N/A), 442 drafting the work (SH, SGL), reviewing the work critically for important intellectual 443 content and final approval of the version to be published (all co-authors). 444 445 Agreement to be accountable for all aspects of the work in ensuring that questions 446 related to the accuracy or integrity of any part of the work are appropriately investigated 447 and resolved (SH, SKS, AC, SGL). 448 449 **COMPETING INTERESTS**

450

The authors declare no competing interest.